Organization
Arch Oncology
2 clinical trials
Clinical trial
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-08-05
Clinical trial
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176Status: Completed, Estimated PCD: 2022-11-17